Cavazzoni: FDA May Loosen Advisory Committee Conflict Of Interest Rules

FDA drug center Director Patrizia Cavazzoni told members of the Biotechnology Innovation Organization that the agency wants to rethink its advisory committee processes, including loosening up conflict of interest rules and removing “some of the emotional” undertones that have been present in recent committee meetings. The agency looks forward to receiving feedback from industry, she said. Cavazzoni’s comments come as the agency faces backlash for approving Biogen’s controversial Alzheimer’s drug despite opposition from members of its own Peripheral and Central...